文献速递青光眼

RANKL抑制剂与高眼压及原发性开角型青光眼风险

RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

这项多国回顾性队列研究基于TriNetX网络2013至2023年数据,纳入40岁以上骨质疏松成人,将接受地舒单抗者与双膦酸盐者按1:1倾向评分匹配后各47,312例。结果显示地舒单抗组5年内发生高眼压(HR=0.72;95%CI,0.59-0.88)和原发性开角型青光眼(HR=0.63;95%CI,0.53-0.75)的风险显著低于双膦酸盐组,敏感性分析和亚组分析结果一致。

要点

  • 地舒单抗组高眼压风险低于双膦酸盐组,HR=0.72(95%CI,0.59-0.88)。
  • 地舒单抗组原发性开角型青光眼风险低于双膦酸盐组,HR=0.63(95%CI,0.53-0.75)。
  • 上述关联在所有敏感性分析和主要亚组中保持一致。

核心结论

  • 在骨质疏松成人中,地舒单抗使用与高眼压和原发性开角型青光眼风险显著低于双膦酸盐治疗相关。

研究设计与样本

  • 多国回顾性队列研究,使用TriNetX网络2013至2023年数据,纳入40岁及以上骨质疏松成人,地舒单抗组与双膦酸盐组按1:1倾向评分匹配,各47,312例。

主要发现

  • 与双膦酸盐治疗相比,地舒单抗使用与高眼压风险显著降低相关(HR=0.72;95%CI,0.59-0.88)。
  • 与双膦酸盐治疗相比,地舒单抗使用与原发性开角型青光眼风险显著降低相关(HR=0.63;95%CI,0.53-0.75)。
  • 上述关联在所有敏感性分析中保持稳健,并在主要患者亚组中一致观察到。

关键数值与推荐

  • 主要结局为5年内新发高眼压和原发性开角型青光眼,采用Cox比例风险模型估计HR及95%CI。
  • 敏感性分析包括将随访延长至10年、要求有眼科就诊以增强诊断有效性、以及调整额外的心血管代谢药物。
  • 亚组分析按年龄、性别、种族、糖尿病和皮质类固醇使用进一步分层。

临床怎么用

  • 对于骨质疏松患者选择地舒单抗或双膦酸盐时,可关注地舒单抗与较低高眼压和原发性开角型青光眼风险的关联。
  • 该关联提示RANKL抑制可能具有眼部相关性,支持通过前瞻性研究进一步探讨其临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether the receptor activator of NF-κB ligand (RANKL) inhibitor denosumab is associated with a lower risk of developing ocular hypertension (OHT) and primary open-angle glaucoma (POAG) compared with bisphosphonate therapy in patients with osteoporosis. METHODS: We conducted a multinational, retrospective cohort study using the TriNetX network from 2013 to 2023. Adults 40 years or older with osteoporosis who received denosumab were propensity score matched 1:1 to those receiving bisphosphonates. The primary outcomes were incident OHT and POAG within 5 years. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses included extending follow-up to 10 years, requiring an ophthalmology visit to strengthen diagnostic validity, and adjusting for additional cardiometabolic medications. Subgroup analyses further stratified participants by age, sex, race, diabetes, and corticosteroid use. RESULTS: After 1:1 propensity score matching, a total of 94,624 patients (47,312 in each cohort) were included in each cohort. Compared with bisphosphonate therapy, denosumab use was associated with a significantly lower risk of developing OHT (HR = 0.72; 95% CI, 0.59-0.88) and POAG (HR = 0.63; 95% CI, 0.53-0.75). These associations remained robust across all sensitivity analyses and were consistently observed across major patient subgroups. CONCLUSIONS: Among adults with osteoporosis, denosumab use was associated with significantly lower risks of OHT and POAG compared with bisphosphonate therapy. These findings highlight the potential ocular relevance of RANKL inhibition and support further investigation into its clinical implications through prospective studies.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Tsai CY, Weng CH, Sheen YJ, et al. RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma. Invest Ophthalmol Vis Sci. 2026. PMID: 42240269. doi:10.1167/iovs.67.6.8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。